LineaBio specializes in the development and manufacturing of induced pluripotent stem cell (iPSC) lines that are compliant with Good Manufacturing Practices (GMP). Their platform, built on over a decade of expertise, allows for the production of high-quality iPSC lines that serve as reliable starting materials for cell therapies. By adhering to GMP standards throughout the entire manufacturing process, LineaBio enhances regulatory compliance and accelerates the development timelines for therapeutic applications, potentially reducing costs by up to 60%. The company offers both unmodified and gene-edited iPSC lines, providing flexibility in licensing options to meet the diverse needs of therapeutic developers.

The iPSC lines are derived from carefully screened donor materials, including cord blood and adult peripheral blood, ensuring that all donors have consented to commercial use in accordance with regulatory requirements. LineaBio employs a rigorous process that includes reprogramming, clonal selection, and extensive quality control testing to guarantee the safety and efficacy of their cell lines. Their offerings include off-the-shelf iPSC lines, which are designed to facilitate quicker access to GMP-compliant materials for clinical use, as well as a transparent licensing structure that supports business planning for developers in the cell therapy space.

Canada

LineaBio's mission is to enable the cell and gene therapy industry by providing access to high-quality, off-the-shelf iPSC lines manufactured under GMP that streamline drug product manufacturing. By allowing therapeutic developers to cut costs and accelerate timelines for GMP reprogramming, LineaBio strives to achieve its vision of making cell therapy universally accessible and affordable. Founded in 2023 by parent companies CCRM and OmniaBio, LineaBio draws on a team of iPSC experts that have been developing an iPSC platform for more than a decade.

LineaBio

Company Details